{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:56:01Z","timestamp":1791212161317,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"vor","delay-in-days":369,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007797","name":"Helsingin Yliopisto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007797","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["643130"],"award-info":[{"award-number":["643130"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["H2020-MSCA-ITN-2014"],"award-info":[{"award-number":["H2020-MSCA-ITN-2014"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004012","name":"Jane ja Aatos Erkon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ymthe.2018.06.001","type":"journal-article","created":{"date-parts":[[2018,7,14]],"date-time":"2018-07-14T22:20:54Z","timestamp":1531606854000},"page":"2243-2254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy"],"prefix":"10.1016","volume":"26","author":[{"given":"Jo\u00e3o Manuel","family":"Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Cervera-Carrascon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riikka","family":"Havunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadia","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Siurala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvi","family":"Sorsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjukka","family":"Anttila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kanerva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akseli","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2018.06.001_bib1","doi-asserted-by":"crossref","first-page":"e1046673","DOI":"10.1080\/2162402X.2015.1046673","article-title":"Trial Watch: Adoptive cell transfer for oncological indications","volume":"4","author":"Aranda","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ymthe.2018.06.001_bib2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2018.06.001_bib3","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1078-0432.CCR-15-1433","article-title":"Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy","volume":"22","author":"Maus","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2018.06.001_bib4","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2018.06.001_bib5","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","article-title":"Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma","volume":"23","author":"Dudley","year":"2005","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2018.06.001_bib6","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(89)91609-7","article-title":"Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer","volume":"1","author":"Kradin","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2018.06.001_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.it.2004.12.003","article-title":"Sinks, suppressors and antigen presenters: how lymphodepletion enhances T\u00a0cell-mediated tumor immunotherapy","volume":"26","author":"Klebanoff","year":"2005","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ymthe.2018.06.001_bib8","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1158\/1078-0432.CCR-16-0049","article-title":"Emerging Opportunities and Challenges in Cancer Immunotherapy","volume":"22","author":"Whiteside","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2018.06.001_bib9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2018.06.001_bib10","first-page":"376","article-title":"Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer","volume":"4","author":"Quatromoni","year":"2012","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.ymthe.2018.06.001_bib11","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1158\/1078-0432.CCR-10-1297","article-title":"CD8+ enriched \u201cyoung\u201d tumor infiltrating lymphocytes can mediate regression of metastatic melanoma","volume":"16","author":"Dudley","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2018.06.001_bib12","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1158\/1078-0432.CCR-13-0380","article-title":"Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies","volume":"19","author":"Besser","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2018.06.001_bib13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/1479-5876-10-169","article-title":"Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients","volume":"10","author":"Ellebaek","year":"2012","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.ymthe.2018.06.001_bib14","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","article-title":"Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial","volume":"23","author":"Andtbacka","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ymthe.2018.06.001_bib15","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2018.06.001_bib16","series-title":"Advances in Cancer Research","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/B978-0-12-398342-8.00008-2","article-title":"Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans","volume":"Volume 115","author":"Cerullo","year":"2012"},{"key":"10.1016\/j.ymthe.2018.06.001_bib17","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/2326-6066.CIR-14-0220-T","article-title":"Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor","volume":"3","author":"T\u00e4htinen","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2018.06.001_bib18","doi-asserted-by":"crossref","first-page":"e97495","DOI":"10.1371\/journal.pone.0097495","article-title":"The in\u00a0vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity","volume":"9","author":"Kleijn","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2018.06.001_bib19","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/mt.2016.137","article-title":"Adenoviral Delivery of Tumor Necrosis Factor-\u03b1 and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma","volume":"24","author":"Siurala","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.06.001_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.omto.2016.12.004","article-title":"Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy","volume":"4","author":"Havunen","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2018.06.001_bib21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/CJI.0000000000000144","article-title":"T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNF\u03b1 Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma","volume":"39","author":"T\u00e4htinen","year":"2016","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.ymthe.2018.06.001_bib22","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00262-015-1691-7","article-title":"Adoptive T\u00a0cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-\u03b3) in metastatic melanoma patients","volume":"64","author":"Khammari","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2018.06.001_bib23","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1002\/ijc.30839","article-title":"Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy","volume":"141","author":"Santos","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2018.06.001_bib24","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.4049\/jimmunol.1200274","article-title":"Blockade of myeloid derived suppressor cells after induction of lymphopenia improves adoptive T\u00a0cell therapy in a murine model of melanoma","volume":"189","author":"Kodumudi","year":"2012","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2018.06.001_bib25","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/mt.2010.161","article-title":"Treatment of cancer patients with a serotype 5\/3 chimeric oncolytic adenovirus expressing GMCSF","volume":"18","author":"Koski","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.06.001_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","article-title":"Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers","volume":"4","author":"Ranki","year":"2016","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2018.06.001_bib27","doi-asserted-by":"crossref","first-page":"e1412902","DOI":"10.1080\/2162402X.2017.1412902","article-title":"TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade","volume":"7","author":"Cervera-Carrascon","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ymthe.2018.06.001_bib28","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00262-005-0018-5","article-title":"Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T\u00a0cells may predict survival in resected advanced-stage melanoma patients","volume":"55","author":"Haanen","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2018.06.001_bib29","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/bjc.2013.32","article-title":"Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer","volume":"108","author":"Ino","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2018.06.001_bib30","doi-asserted-by":"crossref","first-page":"e1136046","DOI":"10.1080\/2162402X.2015.1136046","article-title":"Syngeneic syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting","volume":"5","author":"Siurala","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ymthe.2018.06.001_bib31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc1252","article-title":"Cytokines in cancer pathogenesis and cancer therapy","volume":"4","author":"Dranoff","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2018.06.001_bib32","doi-asserted-by":"crossref","first-page":"9547","DOI":"10.1158\/0008-5472.CAN-05-1175","article-title":"Host lymphodepletion augments T\u00a0cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells","volume":"65","author":"Wang","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2018.06.001_bib33","doi-asserted-by":"crossref","first-page":"711","DOI":"10.4049\/jimmunol.125.2.711","article-title":"Specificity of adoptive chemoimmunotherapy of established syngeneic tumors","volume":"125","author":"Cheever","year":"1980","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2018.06.001_bib34","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3389\/fimmu.2014.00630","article-title":"Plasticity of human CD4 T\u00a0cell subsets","volume":"5","author":"Geginat","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2018.06.001_bib35","doi-asserted-by":"crossref","first-page":"6562","DOI":"10.1128\/JVI.77.11.6562-6566.2003","article-title":"Extensive cross-reactivity of CD4+ adenovirus-specific T\u00a0cells: implications for immunotherapy and gene therapy","volume":"77","author":"Heemskerk","year":"2003","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2018.06.001_bib36","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/ni.2030","article-title":"Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T\u00a0cell lineages","volume":"12","author":"Liao","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2018.06.001_bib37","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1084\/jem.20091918","article-title":"Tumor-reactive CD4(+) T\u00a0cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts","volume":"207","author":"Quezada","year":"2010","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2018.06.001_bib38","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T\u00a0cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2018.06.001_bib39","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.4049\/jimmunol.0801829","article-title":"Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in\u00a0vivo when stimulated with the TLR3 agonist poly(I:C)","volume":"182","author":"Salem","year":"2009","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2018.06.001_bib40","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.4049\/jimmunol.179.9.5936","article-title":"CD86 has sustained costimulatory effects on CD8 T\u00a0cells","volume":"179","author":"Thomas","year":"2007","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2018.06.001_bib41","doi-asserted-by":"crossref","first-page":"99573","DOI":"10.1172\/jci.insight.99573","article-title":"Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T\u00a0cells and cytokine-armed oncolytic adenoviruses","volume":"3","author":"Watanabe","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2018.06.001_bib42","doi-asserted-by":"crossref","first-page":"e0131242","DOI":"10.1371\/journal.pone.0131242","article-title":"Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors","volume":"10","author":"T\u00e4htinen","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2018.06.001_bib43","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.4049\/jimmunol.1100845","article-title":"Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T\u00a0cell depletion and homeostatic proliferation","volume":"188","author":"Kline","year":"2012","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2018.06.001_bib44","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1172\/JCI33522","article-title":"IFN-\u03b3- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers","volume":"118","author":"Zhang","year":"2008","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2018.06.001_bib45","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/sj.bmt.1704763","article-title":"Cardiac toxicity of high-dose chemotherapy","volume":"35","author":"Morandi","year":"2005","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ymthe.2018.06.001_bib46","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.jacc.2017.01.051","article-title":"Pulmonary Hypertension in Heart Failure: Pathophysiology, Pathobiology, and Emerging Clinical Perspectives","volume":"69","author":"Guazzi","year":"2017","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ymthe.2018.06.001_bib47","first-page":"852","article-title":"Vascular Complications of Cancer Chemotherapy","volume":"32","author":"Cameron","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.ymthe.2018.06.001_bib48","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1161\/01.HYP.0000185463.27209.b0","article-title":"Arterial stiffness is related to systemic inflammation in essential hypertension","volume":"46","author":"Mahmud","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.ymthe.2018.06.001_bib49","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1084\/jem.20070657","article-title":"Role of the T\u00a0cell in the genesis of angiotensin II induced hypertension and vascular dysfunction","volume":"204","author":"Guzik","year":"2007","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2018.06.001_bib50","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1161\/01.RES.78.2.329","article-title":"Locally produced tumor necrosis factor-alpha mediates interleukin-2-induced lung injury","volume":"78","author":"Rabinovici","year":"1996","journal-title":"Circ. Res."},{"key":"10.1016\/j.ymthe.2018.06.001_bib51","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1161\/HYPERTENSIONAHA.116.07579","article-title":"CD28\/B7 deficiency attenuates systolic overload-induced congestive heart failure, myocardial and pulmonary inflammation, and activated T\u00a0cell accumulation in the heart and lungs","volume":"68","author":"Wang","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.ymthe.2018.06.001_bib52","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/mt.2015.125","article-title":"Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues","volume":"23","author":"Koski","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.06.001_bib53","doi-asserted-by":"crossref","first-page":"e1265717","DOI":"10.1080\/2162402X.2016.1265717","article-title":"Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy","volume":"6","author":"Zafar","year":"2016","journal-title":"OncoImmunology"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001618302600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001618302600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:52:47Z","timestamp":1761501167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001618302600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1525001618302600"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2018.06.001","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2018.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2018.08.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}